T he promise of cellular therapies as a treatment for stroke and other injuries and diseases of the central nervous system (CNS) has compelled researchers, clinicians, patients, and the public for the last 2 decades. Various types of cells isolated from numerous tissue sources have demonstrated benefit in improving outcomes in animal stroke models when administered intravenously in an acute time frame (minutes to days) after stroke onset. Data supporting the homing of cells to the brain and proximal to the infarct after intravenous administration is lacking, begging the question "How are cells from an array of tissue sources functioning to improve neurological recovery without the presence of the cells at the primary site of injury?"
The last 10 years have seen an increased focus on understanding the importance the peripheral immune system plays in exacerbating and complicating treatment and recovery of patients with stroke. Based on seminal observations from the Willing, Pennypacker, and Offner laboratories, we now know that the spleen participates in the immune response in the acute time frame after stroke onset in animal studies, and the involvement of spleen has now been confirmed in observational human stroke studies. [1] [2] [3] The accumulation of laboratory and clinical data supports the contention that acute intravenous administration of cell therapies provides long-term benefit after stroke by modulating the initial peripheral immune response, potentiating tissue repair and recovery, and these data may collectively signal the emergence of a new class of therapies for the treatment of ischemic stroke.
Peripheral Immune and Spleen Responses After Stroke
After the initial injury in the brain after ischemic stroke, a complex set of inflammatory cascades are initiated resulting in the engagement of both innate and adaptive immune systems. Glial cells-the endogenous phagocytic immune cells of the brain-become activated and in concert with the injured parenchymal tissue, signal the peripheral immune system via secretion of chemokines and cytokines. As innate immune cells respond to these injury signals, chemotaxis and extravasation through the blood-brain barrier begins, via activation and upregulation of vascular adhesion molecules primed by secreted chemokines, and this process is exacerbated by matrix metalloproteinases secreted by infiltrating macrophages and neutrophils to further destabilize the blood-brain barrier. 4 Temporal analysis of the accumulation of different inflammatory cells in the brain of stroke-injured animals indicates that microglia/macrophages are activated by 18 hours and most certainly earlier, and peak by 48 hours after stroke, remaining abundant for as long as 96 hours. 5 Neutrophils peak at 48 hours remaining elevated at 96 hours, whereas T lymphocytes appear later in the process (72-96 hours). These data highlight the intricate but robust response of the peripheral immune system after initiation of the poststroke inflammatory cascade.
The spleen has long been understood as an important immune organ that acts to clear older erythrocytes, cellular debris, and blood borne microorganisms while simultaneously acting as the major reservoir for monocytes and macrophages in the body. 6 Highly organized lymphoid centers are also present in the spleen underscoring the complex functionality of the organ. Over the last decade, a clear physiological response of the spleen to the signals emanating from the initial stroke has been established. 7 The mass of the spleen decreases in the first few days after onset in animal models of stroke, [8] [9] [10] and this response has been validated in humans because 3 separate observational studies have shown splenic volume reduction in patients with stroke in the first few days after symptom onset. [1] [2] [3] Specific correlations relating to the amount of splenic atrophy in patients with stroke were found for inflammatory cytokines (interferon-γ, IL (interleukin)-6, IL-10, IL-12, and IL-13), 2 blood leukocytes, 2,3 and stroke deficit severity. 2 We interpret these clinical findings to suggest that increased splenic atrophy correlates with a more robust peripheral immune response to the stroke, resulting in higher levels of inflammatory cytokines and proinflammatory leukocytes present in the blood, and worse clinical outcomes. Rat stroke studies that label splenocytes before stroke injury and then track the labeled cells provide direct evidence that splenocytes migrate into the blood and subsequently the brain parenchyma after stroke injury, accounting for some of the observed splenic atrophy.
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Additional evidence for spleen-mediated involvement in tissue loss after stroke has been generated in splenectomized, stroke-injured animals. Significant reductions in infarct volumes have been reported by many laboratories in male animals who underwent splenectomy 2 weeks before induction of stroke injury. 10, [12] [13] [14] [15] Splenectomy before inducing injury provides significant improvements in tissue preservation, mortality, and behavioral outcomes in an intracerebral hemorrhage model, 16 a rat hypoxic-ischemic (HI) injury model, 17 and in rodent models of traumatic brain injury (TBI). 18, 19 Splenectomy 2 weeks before stroke in female rodents had no effect on infarct volume compared with sham splenectomized females, 15 and spleen removal in male rats immediately (minutes) before inducing stroke injury worsened outcomes when compared with a sham splenectomy stroke group, 20 illustrating that aspects of the spleen/brain axis after injury remain to be elucidated and presenting the opportunity to investigate whether and how cellbased therapies could participate in modulating this axis.
Efficacy of Intravenous Administration of Cellular Therapies in Animal Stroke Models
Cells derived from different tissue sources, including bone marrow mononuclear cells, 21 mesenchymal stem cells from bone marrow, 22 hemopoietic stem cells, 23 adipose-derived stem cells, 24 human umbilical cord blood cells (HUCBs), 25, 26 placenta, 27 neural stem cells (NSCs), 16 and amniotic sources, 28 have all been shown to decrease neuronal injury in animal models of stroke when administered intravenously. Data from animal stroke studies testing hemopoietic stem cells, bone marrow mononuclear cells, NSCs, and HUCBs demonstrate the ability of these disparate cell types to specifically modulate the peripheral immune response, and in the case of NSC, hemopoietic stem cells, 23 and HUCB, 26 these cells seem to exert this effect via interactions with the spleen. Intravenous administration of HUCB within 24 hours of stroke blunts splenic atrophy, perhaps limiting the egress of immune cells from the spleen into the periphery and eventually into the brain in response to the injury. 8, 26 Studies with multipotent adult progenitor cells (MAPCs)-a distinctive adult, adherent cell type-have extended the understanding of how intravenous administration of cellular therapies engage and modulate the peripheral immune system after stroke. MAPCs can be isolated from bone marrow and other tissues 29 and are well characterized, unique from bone marrow mononuclear cells and mesenchymal stem cells based on size, 30 transcriptome, 31 secretome, 32 miRNA profile, and differentiation capability. 33, 34 In 1 study, MAPC exerted more robust tissue sparing and mitigation of glial activation when compared with mesenchymal stem cells after intraparenchymal administration in mouse experimental models of stroke. 35 Subsequently, MAPCs were shown to be effective when given intravenously in a rat model of stroke, 36 with a defined dose response and window of therapeutic administration resulting in statistically significant tissue sparing and improvements in locomotor and neurological outcomes compared with vehicletreated stroke-injured animals.
A preclinical rat study by Yang et al 10 confirmed that intravenous MAPC administration enhances stroke recovery by modulating the peripheral immune system via specific interactions between MAPC and splenocytes. Similar to results testing HUCB, intravenous administration of MAPC within 24 hours blocks the decrease in splenic mass after stroke. Labeled MAPCs distribute to the spleen in an injury-dependent way, and MAPC administration resulted in significant decreases in terminal deoxynucleotidyl transferase dUTP nick end labeling-positive apoptotic cells in the spleen compared with vehicle-treated stroke animals. Cell-treated stroke animals showed statistically significant decreases in CD3+, CD4+, and CD8+ cells and significant increases in FoxP3+ (forkhead box protein P3) T regulatory cells isolated from spleen, compared with splenocyte analyses from saline-treated stroke animals. Decreases in the inflammatory cytokines IL-1β and TNF-α (tumor necrosis factor alpha) were also observed in splenocyte cultures from MAPC-treated animals when compared with splenocytes from saline-treated animals with a converse increase in the anti-inflammatory cytokine IL-10 observed in the MAPC treatment group.
Intravenous MAPC-treated animals displayed sustained and statistically significant improvement in locomotor and neurological functions compared with saline-treated stroked animals out to 28 days post-injury. Significant preservation of brain tissue after the stroke was observed in the cell-treated animals at 28 days post-injury compared with the salinetreated group. Interestingly, the difference in brain lesion volumes 96 hours after stroke onset (72 hours after either MAPC or saline treatment) was negligible between the 2 groups, suggesting that cells administered at 24 hours were unable to rescue or preserve tissue in the focal core of the injury, but rather slowed or completely blunted the increase in parenchymal tissue loss over the following 4 weeks.
To confirm the importance of the spleen in directly potentiating the beneficial effects of intravenously administered MAPC after stroke, experiments were performed comparing stroke-injured splenectomized animals to sham splenectomized stroke-injured animals. Data confirmed that removal of the spleen 14 days before onset of stroke results in a statistically significant decrease in lesion volume compared with animals with intact spleens. Intravenous administration of MAPC could further preserve brain tissue in the splenectomized animals suggesting that MAPCs are able to effect injury expansion via nonspleen-mediated mechanisms as well. MAPC treatment was also able to alter serum IL-6 and IL-1β levels in animals with or without spleens, although levels of IL-6 were reduced 3-fold in the serum of splenectomized animals versus normal, suggesting the spleen may be a major source for increase in systemic IL-6 levels after injury. Serum upregulation of IL-10 was only observed in animals that had intact spleens, had a stroke injury, and had been administered intravenous MAPC, suggesting that the physical presence of MAPC in the spleen is able to initiate a 10-to 15-fold increase in IL-10 in the serum 3 days after stroke onset. This upregulation is dependent on the presence of the spleen and the intravenous administration of MAPC after stroke onset. In the absence of either the cells or the spleen, no IL-10 was detected in the serum. The intravenous administration of MAPC 24 hours after experimental stroke in splenectomized animals resulted in no significant difference in neurological improvement when compared with stroke-injured splenectomized animals treated with saline. These results parallel another study in which intravenously administered NSCs reduced inflammatory responses
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within the spleen and brain in a rodent model of brain hemorrhage while splenectomy abolished these treatment effects of the NSCs. 16 In addition to stroke, studies performed in other animal models of acute CNS injury, in different species and with multiple independent academic research collaborators, provide support for a conserved mechanism of benefit for intravenous cell therapy. 30 Published data in animal models of TBI and spinal cord injury confirm that intravenous administration of labeled MAPCs 24 hours after the induction of an injury results in accumulation of cells in the spleen as compared with other organs. 18, 37 In the absence of the induction of an injury, cells do not preferentially accumulate in the spleen. Counter to conventional thinking, MAPCs neither home to nor accumulate at the site of injury in the CNS. Injury-induced splenic atrophy has been reported in TBI 18 and HI injury, 38 and intravenous administration of MAPCs significantly blocks injury-induced splenic atrophy when administered within 24 hours in each of these preclinical animal injury models.
The effects that intravenous MAPC administration has on modulation of the peripheral and local immune response have been conserved in other animal models of acute neurological injury. A decrease in inflammatory cytokines from the spleen of cell-treated TBI-injured animals 18 and in the serum of celltreated HI-injured animals 38 has been observed. Evidence for MAPC-mediated inhibition of microglial activation has been published in models of stroke, 35 TBI, 39 and HI injury. 38 In addition to demonstrating this effect on microglia, MAPC treatment increases tissue sparing in spinal cord injury 37 and HI injury, 38 resulting in significant improvements in neurological and locomotor outcomes.
MultiStem Phase 2 Clinical Trial Data
With the accumulation of preclinical animal data supporting the benefits of intravenous administration of MAPC for the treatment of CNS injury, a phase I/II clinical trial was undertaken testing the safety and efficacy of MultiStem (the name for the clinical product for MAPC) in the treatment of patients with acute ischemic stroke. The MASTERS trial (MultiStem in Acute Stroke Treatment to Enhance Recovery Study) was conducted in 33 clinical centers in the United States and United Kingdom from October 2011 through December 2015. 40 This randomized, double-blind, placebo-controlled study of 126 patients enrolled patients 24 to 48 hours after stroke onset and generated important information on the clinical translation of intravenous administration of cellular therapies.
First, the results demonstrated that intravenous MultiStem treatment was safe and well tolerated during the course of the study. There was no difference between MultiStem and placebo treatment in the incidence of adverse events, and adverse events were consistent with expectations for patients after ischemic stroke. There were no infusion-related allergic reactions and no cases of neurological worsening between the MultiStem and placebo-treated subjects. MultiStem treatment was associated with lower rates of life-threatening adverse events or death and of secondary infections. The results also indicated that MultiStem treatment had meaningful impact on decreased time in the intensive care unit and decreased overall hospitalization time compared with placebo-treated patients.
These end points were prespecified exploratory end points based on the hypothesis from preclinical animal data suggesting that intravenous administration of cells resulted in a mitigation of the peripheral immune response to the stroke and would, therefore, likely result in a decrease in immune-related adverse events in the cell-treated patients. Consistent with this hypothesis, exploratory analysis of data from serum samples of study subjects suggested that MultiStem treatment significantly reduces biomarkers of poststroke inflammation compared with placebo. Average circulating CD3+ T cells were reduced at day 2 after randomization in MultiStem subjects and increased in placebo subjects, resulting in a statistically significant difference (P<0.01). Inflammatory cytokine levels were reduced significantly by day 7 after randomization in the MultiStem treatment group compared with the placebo group. Both exploratory analyses were again prespecified based on the translational animal data from experimental stroke studies suggesting that intravenous MAPC administration significantly decreased CD3+ cells and inflammatory cytokines compared with analysis of saline-treated stroke animals. 10 The primary end point, global stroke recovery using a composite test statistic at 90 days after treatment, was not statistically significant, nor were any of the prespecified secondary end points. Post hoc analyses of the efficacy data, however, suggested that MultiStem treatment may provide benefit when administered in an earlier time window of 24 to 36 hoursa time frame that was specified in the original protocol. This optimized treatment time was based on results from preclinical experimental stroke animal data. 36 However, because of logistical issues at some clinical sites, qualified patients were being missed in the 24-to 36-hour window, and the treatment time was extended to 24 to 48 hours to increase enrollment rates. This protocol amendment and the addition of 12 hours to perform intravenous administration of the cells may have impacted the trial results. As shown in Figure 1 below, when the entire intent-to-treat population of the trial was examined, the MultiStem group had a nonsignificant trend of achieving an Excellent Outcome (patients achieving an National Institutes of Health Stroke Scale of 0 or 1 and a modified Rankin Scale score of 0 or 1 and a Barthel Index of ≥95) when compared with the placebo treatment group. The difference between the cell and placebo groups becomes more pronounced when analysis of patients under the original protocol (ie, patients receiving cells <36 hours after stroke onset) is performed. Interestingly when these same patients were analyzed 1 year after treatment, the differences between the cell treatment group were statistically significant in the entire intent-to-treat group and more pronounced in the early MultiStem group. At 1 year, earlytreated MultiStem subjects had a significantly higher chance of excellent outcomes-full or nearly full recovery-than placebo subjects. Almost one third of the early-treated MultiStem subjects achieved this outcome compared with less than one tenth of placebo subjects. The results of this study provide a foundation for moving forward with the next phase of development of intravenous administration of the MultiStem cell therapy for the treatment of ischemic stroke.
Hypothesis for Intravenous Cell TherapyMediated Benefit
When considering the accumulation of consistent translational data, from preclinical animal injury models to human clinical results from the MASTERS-1 trial, a hypothesis emerges (Figure 2 ) suggesting the potential for intravenous administration of cellular therapies in modulating the acute, adverse contributions of the peripheral immune system after ischemic stroke. Is it possible that a single intravenous administration of cells 24 to 36 hours after stroke onset can mitigate and rebalance the immune response to the initial focal ischemic injury sufficient to allow for neural repair and improved long-term outcomes? As discussed earlier, the activation, migration, and participation of immune cells from the periphery, maybe most importantly from the spleen, is a critical step in the progression of poststroke pathophysiology. Selectively preventing activated peripheral proinflammatory immune cells and cytokines from crossing the blood-brain barrier and into the parenchyma is likely a critical step in attenuating the propagation of proinflammatory microglial activation (eg, M1 microglia), neuronal die-back, and expansion of tissue loss. Removal of the spleen before inducing stroke or TBI in male animals results in less tissue loss and a less disrupted blood-brain barrier, respectively, highlighting the participation of cells from the spleen. Intravenous administration of MAPC in rat models of ischemic stroke, as well as MultiStem in adult stroke in the MASTERS-1 study, resulted in significantly decreased levels of CD3+ cells in serum compared with placebo treatment. 10, 40 As stated previously, removal of the spleen before inducing ischemic stroke results in increased tissue sparing and intravenous administration of MAPC into splenectomized stroke-injured animals results in additional tissue sparing. 10 However, MAPC-treated stroke-injured animals who had undergone splenectomy showed no significant locomotor or neurological improvements compared with placebo-treated stroke-injured animals. This was not the case in MAPCtreated stroke-injured animals with spleens. Simply inhibiting the participation of the splenic component of the peripheral immune system allows for tissue sparing but is not sufficient for enabling neurological and locomotor benefit. Is it possible to reconcile these 2 observations? What if the intravenous administration of cellular therapies is simultaneously acting to block the adverse aspects of the peripheral immune response, while simultaneously accelerating or promoting reparative physiology that temporally is not engaged until later in the normal process of wound repair?
Preclinical studies in animal models of stroke, TBI, and spinal cord injury have all demonstrated that intravenous administration of MAPC 24 hours after injury results in a statistically significant upregulation of T regulatory cells in the spleen or the blood of the cell-treated animals compared with vehicle treatment. T regulatory cells have been identified as neuroprotective in numerous animal models of CNS injury, [41] [42] [43] although there are contradicting data for the efficacy of T regulatory activity poststroke. 44, 45 Our data support the contention that MAPC treatment can upregulate T regulatory cell levels after acute injury and suggest that this upregulation correlates with improvement in cell-versus vehicle-treated injured animals. A publication from Melief et al 46 suggests that T regulatory cells can be upregulated via an IL-10-mediated pathway or a secondary alternatively activated or M2 macrophage-mediated pathway. We have previously highlighted that MAPC-treated stroke-injured animals have a statistically significant upregulation of serum IL-10 that is not observed in the absence of injury, cell treatment, or the spleen. Furthermore, in MAPCtreated TBI-injured animals, there is a statistically significant upregulation of M2 macrophages/microglia in the brain when compared with vehicle-treated TBI animals. 47 These studies suggest both aspects of the T regulatory cell upregulation mechanisms discussed by Melief have been observed in different CNS injury models when animals have been treated with MAPC.
The implications for intravenous administration for cellular therapies and their potential in promoting recovery after stroke via a T regulatory cell-mediated process has become even more intriguing based on 2 recent publications. A review of the potential mechanisms through which cellular therapies may provide benefit after stroke or TBI identified modulation of microglia as a critical element to target in stroke recovery, 48 and modulation of microglia has been linked to T regulatory cells in an animal model of hemorrhagic stroke. 49 T regulatory 
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cells specifically increased the alternatively activated M2 or reparative phenotype of microglia via an IL-10-mediated mechanism. This result highlights the potential of T regulatory cells and potential downstream effectors via IL-10 or M2 alternatively activated microglia/macrophage phenotypes, which have been reported previously in MAPC animal studies. A summary of this mechanism is depicted in Figure 2 . Second, Dombrowski et al 50 recently reported that T regulatory cells can directly promote oligodendrocyte cell differentiation and myelination in vivo. This result suggests that T regulatory cells could directly impact neural pathway recovery and repair after injury or demyelination in the CNS. A recent phase II clinical study at the UTHealth-Houston examining the safety and efficacy of intravenous administration of autologous bone marrow mononuclear cells in treatment of TBI found preservation of white matter tracts in the cell treatment group compared with the vehicle treatment group. 51 Although speculative, these publications taken together raise the possibility that intravenous administration of certain cellular therapies may impact multiple different aspects of the immune system, in some cases to limit or suppress activity, in other ways to activate or enhance activity, resulting in the potential for less tissue damage and enhanced recovery, potentially through multiple mechanisms, after an ischemic stroke or other acute severe injuries of the CNS.
Future Trials and Variables to be Addressed
After the publication of the MASTERS-1 trial results, a Phase III trial named MASTERS-2 has been designed to extend our knowledge and understanding of the hypothesis for using MultiStem to treat patients with ischemic stroke and is scheduled to begin enrolling patients in 2018. This pivotal doubleblind, placebo-controlled trial will enroll ≈300 patients in at least 50 clinical sites globally and has received a Special Protocol Assessment Designation, Fast Track Status, and a Regenerative Medicine Advanced Therapy Designation from the FDA based up on a review of the product, preclinical data, and safety and clinical data from the MASTERS-1 trial. Based on our hypothesis relating to the potential mechanisms of action, exploratory end points, including ultrasound measurement of the spleen, white matter track reorganization via diffusion tensor imaging, and T regulatory cell measurements, will be evaluated in MASTERS-2. Additionally, a second pivotal trial testing the safety and efficacy of the MultiStem product in the treatment of patients with acute ischemic stroke in Japan is currently underway-TREASURE study Figure 2 . A model hypothesis for how multipotent adult progenitor cells (MAPC) enhance recovery after stroke. In the untreated scenario, ischemic stroke leads to the activation of the peripheral immune system, including spleen reduction and the release from the spleen of proinflammatory cells and cytokines. These proinflammatory mediators contribute to worsening blood-brain barrier (BBB) disruption and central nervous system (CNS) inflammation mediated by M1 microglia. An intravenous administration of MAPC reverses splenic atrophy, promotes the release of anti-inflammatory mediators from the spleen, which ultimately leads to less BBB disruption and less CNS inflammation, and the promotion of a proregenerative environment. IL indicates interleukin; and Tregs, T regulatory cells.
(Treatment Evaluation of Acute Stroke Using Regenerative Cell Elements).
Although these 2 trials will provide the opportunity to better evaluate and examine the proposed mechanism of action through which we believe intravenous administration of cellular therapies provides benefit after stroke, additional preclinical and clinical studies are required moving forward to ensure a more complete understanding. Although extensive dose ranging was performed in preclinical animal stroke models, and in a limited way in MASTERS-1, a more thorough evaluation of dose ranging may provide important information. Evaluating the safety and efficacy of multiple dose administrations and different times may also yield new information. Understanding the safety and potential efficacy for cells that are pretreated or prestimulated with ≥1 cytokines or immunomodulatory factors may also provide new topics for experimentation.
Conclusions
As opposed to small molecule drugs with a single target and molecular mechanism of action, intravenous administration of cellular therapies appears dynamic with the potential to act on and engage multiple mechanisms of action. This approach may be the type of multimodal therapy required to treat a condition like stroke, which unleashes many pathologies downstream of the initial ischemic event. Intravenous administration of therapeutic cells can mitigate the engagement of the peripheral proinflammatory immune response after stroke and other acute injuries of the CNS. By reducing the presence of proinflammatory cells and cytokines emanating, in part, from the spleen, the timely administration of MAPC/ MultiStem cells seems to result in improved recovery in animals, and the MASTERS-1 trial suggests similar benefit in humans. Although our review focuses on cell-based therapies for acute ischemic stroke, several early-stage clinical trials have been conducted, testing various types of bone marrow and adipose-derived cell types with an intravenous administration, but nearly all of them address patients in subacute or chronic time windows, 52, 53 which may involve other mechanisms of action to improve stroke recovery.
Our analysis begs the question, if reducing the involvement of the immune system in acute ischemic stroke is the key to recovery, then what about other well-characterized agents like steroids or immune cell neutralizing antibodies? A review of data from 7 independent clinical trials involving 453 patients with stroke determined that the administration of steroids provides no meaningful survival or functional outcome benefit compared with standard of care. 54 No additional randomized trials accessing the therapeutic potential of steroids in stroke have been listed at http://clinicaltrials.gov in >15 years. A prior randomized trial had already shown the harmful effects of steroids in patients with intracerebral hemorrhage. 55 More recently, a review of trials on the safety and efficacy of immunomodulatory therapies, including small molecules, neutralizing antibodies against inflammatory cytokines, or cell epitopes involved in immune cell extravasation into the brain poststroke, was published. 56 Although most of the trials had been terminated because of futility (minocycline, inhibiting neutrophil adhesion to the endothelium via CD11b or CD18 receptor antibodies, and inhibiting leukocyte attachment and extravasation via an antibody against the intercellular adhesion molecule-1), there have been modest signs of treatment effects in a few phase II trials. Larger studies will be forthcoming on inhibiting the peripheral immune system after stroke, via neutralizing antibodies. However, at this time, the use of either a global immunosuppressant, like steroids, or the blockage of immune cell egress into the brain through administration of neutralizing antibodies, may not to be sufficient to provide meaningful recovery benefit in treatment of patients with ischemic stroke.
The proposition that directly modulating the involvement of the peripheral immune system after an acute ischemic stroke is an evolving aspect of clinical science for this patient population. The concept that intravenous administration of a cellular therapy could simultaneously inhibit potential detrimental aspects of our innate immune system's response to the stroke while simultaneously accelerating the beneficial or reparative response is a novel aspect of this hypothesis. We now need a more complete understanding of the involvement of T regulatory cells and alternatively activated microglia/ macrophages, the inhibition of glial activation, and of oligodendrocyte activation and white matter recovery as a function of intravenous administration of cell therapy. We look forward to the phase 3 trials, MASTERS-2, and TREASURE, as well as other planned studies for definitive data on the efficacy of cellular therapy and the mechanisms of action through which they seem to provide benefit after intravenous administration.
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